Patient characteristics at baseline
| . | 100 mg BID (n = 24) (%) . | 200 mg QD (n = 24) (%) . | Total (n = 48) (%) . |
|---|---|---|---|
| Disease status | |||
| Treatment-naive | 6 (25.0) | 10 (41.7) | 16 (33.3) |
| R/R | 18 (75.0) | 14 (58.3) | 32 (66.7) |
| Histology | |||
| CLL | 22 (91.7) | 21 (87.5) | 43 (89.6) |
| SLL | 2 (8.3) | 3 (12.5) | 5 (10.4) |
| Baseline Rai stage | |||
| 0 (low risk) | 0 | 0 | 0 |
| I-II (intermediate risk) | 15 (62.5) | 11 (45.8) | 26 (54.2) |
| III-IV (high risk) | 7 (29.2) | 11 (45.8) | 18 (37.5) |
| Missing | 2 (8.3) | 2 (8.3) | 4 (8.3) |
| Bulky disease | |||
| ≥5 cm | 11 (45.8) | 7 (29.2) | 18 (37.5) |
| Genetic aberrations | |||
| Del 17p/TP53 mutation | 4/19 (21.1) | 9/21 (42.9) | 13/40 (32.5) |
| Del 17p only | 1/20 (5.0) | 1/21 (4.8) | 2/41 (4.9) |
| TP53 mutation only | 2/20 (10.0) | 3/22 (13.6) | 5/42 (11.9) |
| Both del 17p and TP53 mutation | 1/19 (5.3) | 5/21 (23.8) | 6/40 (15) |
| Del 11q | 4/20 (20.0) | 5/21 (23.8) | 9/41 (22.0) |
| NOTCH1 mutation | 8/20 (40.0) | 11/22 (50.0) | 19/42 (45.2) |
| IGHV | |||
| Unmutated | 17 (70.8) | 20 (83.3) | 37 (77.1) |
| Mutated | 3 (12.5) | 2 (8.3) | 5 (10.4) |
| B2-microglobulin | |||
| >3.5 mg/L | 11 (45.8) | 9 (37.5) | 20 (41.7) |
| . | 100 mg BID (n = 24) (%) . | 200 mg QD (n = 24) (%) . | Total (n = 48) (%) . |
|---|---|---|---|
| Disease status | |||
| Treatment-naive | 6 (25.0) | 10 (41.7) | 16 (33.3) |
| R/R | 18 (75.0) | 14 (58.3) | 32 (66.7) |
| Histology | |||
| CLL | 22 (91.7) | 21 (87.5) | 43 (89.6) |
| SLL | 2 (8.3) | 3 (12.5) | 5 (10.4) |
| Baseline Rai stage | |||
| 0 (low risk) | 0 | 0 | 0 |
| I-II (intermediate risk) | 15 (62.5) | 11 (45.8) | 26 (54.2) |
| III-IV (high risk) | 7 (29.2) | 11 (45.8) | 18 (37.5) |
| Missing | 2 (8.3) | 2 (8.3) | 4 (8.3) |
| Bulky disease | |||
| ≥5 cm | 11 (45.8) | 7 (29.2) | 18 (37.5) |
| Genetic aberrations | |||
| Del 17p/TP53 mutation | 4/19 (21.1) | 9/21 (42.9) | 13/40 (32.5) |
| Del 17p only | 1/20 (5.0) | 1/21 (4.8) | 2/41 (4.9) |
| TP53 mutation only | 2/20 (10.0) | 3/22 (13.6) | 5/42 (11.9) |
| Both del 17p and TP53 mutation | 1/19 (5.3) | 5/21 (23.8) | 6/40 (15) |
| Del 11q | 4/20 (20.0) | 5/21 (23.8) | 9/41 (22.0) |
| NOTCH1 mutation | 8/20 (40.0) | 11/22 (50.0) | 19/42 (45.2) |
| IGHV | |||
| Unmutated | 17 (70.8) | 20 (83.3) | 37 (77.1) |
| Mutated | 3 (12.5) | 2 (8.3) | 5 (10.4) |
| B2-microglobulin | |||
| >3.5 mg/L | 11 (45.8) | 9 (37.5) | 20 (41.7) |